HWHaiyan Wang

Haiyan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haiyan Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Hailiang Li

    Ningxia Key Laboratory of Craniocerebral Diseases, Yinchuan, China

    2 shared publications
  • Li Hou

    Department of Otolaryngology, Head and Neck Surgery, General Hospital of Ningxia Medical University, Yin Chuan, P. R. China

    2 shared publications
  • Bo-Yu Zhang

    School of Clinical Medicine Fujian Medical University, Fuzhou, 350000, P.R. China

    1 shared publication
  • Dede Ma

    Ningxia Medical University, Yin Chuan, P. R. China

    1 shared publication
  • Faxuan Wang

    School of Public Health, Ningxia Medical University, Yinchuan 750004, China

    1 shared publication
  • Haitao Ran

    Department of Ultrasound, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China; Chongqing Key Laboratory of Ultrasound Molecular Imaging and Therapy, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China

    1 shared publication

Latest Publications

  • 18F-FDG simultaneous PET/MR monitoring treatment response of a Turcot syndrome case

    by Haiyan Wang, Qiaoyi Xue, Zhiwen You, Xing Chen, Jianmin Yuan, Jun Zhao

  • The circadian clock gene PER2 enhances chemotherapeutic efficacy in nasopharyngeal carcinoma when combined with a targeted nanosystem

    by Li Hou, Hailiang Li, Haiyan Wang, Dede Ma, Jing Liu, Liqiong Ma, Zhihua Wang, Zhihua Yang, Faxuan Wang, Hechun Xia

    Treatment failure occurs in more than 40% of advanced nasopharyngeal carcinoma (NPC) patients including local recurrence and distant metastasis due to chemoradioresistance. Circadian clock genes were identified as regulating cancer progression and chemoradiosensitivity in a time-dependent manner. A novel nanosystem can ensure the accumulation and controllable release of chemotherapeutic agents at the tumour site at a set time. In this study, we investigated the expression of circadian clock genes and identified that period circadian regulator 2 (PER2) as a tumour suppressor plays a key role in NPC progression. A label-free proteomic approach showed that PER2 overexpression can inhibit the ERK/MAPK pathway. The chemotherapeutic effect of PER2 overexpression was assessed in NPC together with the nanosystem comprising folic acid (FA), upconverting nanoparticles covalently coupled with Rose Bengal (UCNPs-RB), 10-hydroxycamptothecin (HCPT) and lipid-perfluorohexane (PFH) (FURH-PFH-NPs). PER2 overexpression combined with the targeted and controlled release of nanoagents elevated chemotherapeutic efficacy in NPC, which has potential application value for the chronotherapy of tumours.


  • A nanosystem loaded with perfluorohexane and rose bengal coupled upconversion nanoparticles for multimodal imaging and synergetic chemo-photodynamic therapy of cancer

    by Hai-Yan Wang, Li Hou, Hai-Liang Li, Xu Wang, Yang Cao, Bo-Yu Zhang, Jing-Tao Wang, Shi-Jie Wei, Hong-Wan Dang, Hai-Tao Ran

    Theranostics is a new trend integrating diagnostic and therapeutic functions in tumour research. Theranostic nanoparticles enabling both tumour imaging and drug delivery are a promising platform for image-guided cancer therapy. Photodynamic therapy (PDT) has great potential in synergy with traditional chemotherapy but faces great challenges due to hypoxia, poor targeting ability and the limited penetration depth of visible light. To solve these problems, we presented a novel nanosystem of FA/UCNPs–RB/HCPT/PFH@lipid (denoted as FURH-PFH-NPs), with a perfluorohexane (PFH) carrying rich oxygen core and a folic acid-modified lipid shell. The shell contains 10-hydroxycamptothecin (HCPT) and self-fluorescing photosensitizer compounds, namely, upconversion nanoparticles and rose bengal (UCNPs–RB). In this study, FURH-PFH-NPs aggregated in SKOV3 cells (in vitro) and the nude xenograft tumour region when combined with folic acid receptors. When triggered by low-intensity focused ultrasound (LIFU), FURH-PFH-NPs released PFH, UCNPs–RB and HCPT. The above procedure was monitored through multimodal imaging, which simultaneously guided the tumour therapy. UCNPs–RB and PFH promoted the PDT effect under LIFU. Through PDT and HCPT, we obtained better therapeutic effects and good biosafety against SKOV3 nude xenograft tumours. FURH-PFH-NPs combined with LIFU and laser irradiation might be a promising strategy for ovarian cancer.